Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

Over the past ten years, the Cardiovascular Research Laboratory at Spaulding has refined a unique form of exercise for those with spinal cord injuries (SCI). Functional Electrical Stimulation Row Training (FESRT) couples volitional arm and electrically controlled leg exercise, resulting in the benefits of large muscle mass exercise. However, despite the potential for enhancing aerobic capacity by training the denervated leg skeletal muscle via hybrid FES exercise, the inability to increase ventilation beyond limits set by high level SCI restricts aerobic capacity.

This research study will investigate two potential methods of improving ventilation in those with high-level SCI through a double-blind randomized trial. One method is non-invasive ventilation (NIV), which is an external breathing support machine. The second method is the use of Buspar, a drug, which has been used to treat respiratory dysfunction after SCI in rats and some human case reports.

In this study, participants will engage in a 6-month FES row training program while receiving either NIV or shamNIV and Buspar or placebo, and under study tests to evaluate cardiopulmonary health and fitness.

Study Overview

• Status: Recruiting
• Conditions: Spinal Cord Injuries
• Intervention / Treatment: Drug: Buspirone Hydrochloride; Device: Noninvasive Ventilation (NIV); Other: Functional Electrical Stimulation Row Training (FESRT); Drug: Buspirone placebo; Device: Sham Non-invasive ventilation (NIV)

Detailed Description

Regular aerobic exercise with sufficient intensity can improve overall health, however daily energy expenditure is low in those with SCI, especially in those with high level lesions. The investigators have developed Functional Electrical Stimulation Row Training (FESRT) that couples volitional arm and electrically controlled leg exercise, increasing the active muscle and resulting in benefits of large muscle mass exercise. Despite the potential for enhancing aerobic capacity, those with high level lesions (T3 and above) have a remaining obstacle to attaining higher work capacities: a level of pulmonary muscle denervation. The investigators preliminary work suggests this limits the aerobic capacity that can be achieved with FESRT.

External ventilatory support could improve the ability to exercise train and hence enhance the adaptations to chronic exercise in high level SCI. Non invasive ventilation (NIV) during exercise training has been shown to improve gains in exercise capacity in those with similarly restrictive breathing. Therefore, the investigators hypothesize that the use of NIV during FESRT will reduce ventilatory limits to exercise, leading to increased aerobic capacity in high level SCI. In addition, pharmacologic treatments may augment respiratory control and improve exercise ventilatory responses. Buspirone can reverse respiratory abnormalities consequent to SCI in rats, and humans case reports suggest successful Buspirone treatment of respiratory dysfunction

Therefore, the investigators propose a double-blind 2x2 trial of 6 months of FESRT with NIV or Sham and Buspirone or Placebo in individuals with acute, high-level SCI. The investigators hypothesize that both NIV and Buspirone will improve ventilatory exercise responses and that combined treatment will have the greatest effect. This will result in greater improvements in aerobic capacity and concomitant increases in pulmonary function and reductions in cardiometabolic risk. This work proposes two approaches to overcome ventilatory limitations to exercise in high level SCI and allow for greater improvements in cardiopulmonary capacity - one that overcomes mechanical limitations of paralyzed pulmonary musculature and one that treats loss of serotonergic respiratory control, both of which may contribute to blunted ventilatory responses. The ultimate purpose of this research is to optimize exercise for a population that both needs and seeks the broad range of benefits that exercise can confer.

• Study Type: Interventional
• Enrollment (Anticipated): 70
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Cambridge, Massachusetts, United States, 02138
      • Recruiting
      • Spaulding Hospital Cambridge

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• SCI outpatients aged 18-45 years
• medically stable
• body mass index 18.5-30 kg/m2 to include normal to overweight but not obese individuals
• 3-months to 6-years post-injury
• ASIA Scale A, B, or C injury at or above neurological level T4
• able to follow directions
• wheelchair users
• leg muscles responsive to stimulation

Exclusion Criteria:

• BP >140/90 mmHg to exclude for hypertension (though rare in those with high level SCI)
• current tobacco users
• significant arrhythmias
• coronary disease
• diabetes
• renal disease
• cancer
• epilepsy
• current use of cardioactive medications (except medication to support blood pressure)
• current grade 2 or greater pressure ulcers at relevant contact sites
• other neurological disease
• peripheral nerve compressions or rotator cuff tears that limit the ability to row
• history of bleeding disorders
• current use of buspirone
• pregnancy
• contraindications to Buspirone (taking MAO inhibitors, known hypersensitivity to buspirone, benzodiazepine dependence, akathisia, renal impairment, hepatic disease)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NIV + Buspar; Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.	Drug: Buspirone Hydrochloride; Subjects take 30 mg buspirone HCl twice a day for 6 months.; Other Names: Buspar; Device: Noninvasive Ventilation (NIV); The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.; Other: Functional Electrical Stimulation Row Training (FESRT); Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Placebo Comparator: NIV + placebo; Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.	Device: Noninvasive Ventilation (NIV); The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.; Other: Functional Electrical Stimulation Row Training (FESRT); Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.; Drug: Buspirone placebo; Subjects take a placebo tablet twice a day for 6 months.
Sham Comparator: sham NIV + Buspar; Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.	Drug: Buspirone Hydrochloride; Subjects take 30 mg buspirone HCl twice a day for 6 months.; Other Names: Buspar; Other: Functional Electrical Stimulation Row Training (FESRT); Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.; Device: Sham Non-invasive ventilation (NIV); The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Active Comparator: sham NIV + placebo; Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.	Other: Functional Electrical Stimulation Row Training (FESRT); Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.; Drug: Buspirone placebo; Subjects take a placebo tablet twice a day for 6 months.; Device: Sham Non-invasive ventilation (NIV); The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in baseline aerobic exercise capacity	Participants perform incremental FES rowing exercise test to determine maximum oxygen consumption (VO2 peak)	Baseline, 3 months, 6 months
Change in baseline ventilation during exercise	Participants perform incremental FES rowing exercise test to determine ventilation during exercise (VE peak).	Baseline, 3 months, 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in glucoregulatory status	Blood will be taken via standard venipuncture to measure the homeostasis model assessment (HOMA) of insulin resistance.	Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status	Blood will be taken via standard venipuncture to measure the quantitative insulin check index (QUICKI).	Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status	Blood will be taken via standard venipuncture to measure hemoglobin A1c.	Baseline, 3 months, 6 months
Change from baseline in serum lipids	Blood will be taken via standard venipuncture to measure plasma total cholesterol.	Baseline, 3 months, 6 months
Change from baseline in serum lipids	Blood will be taken via standard venipuncture to measure low-density lipoprotein cholesterol.	Baseline, 3 months, 6 months
Change from baseline in serum lipids	Blood will be taken via standard venipuncture to measure high density apolipoprotein cholesterol.	Baseline, 3 months, 6 months
Change from baseline in serum lipids	Blood will be taken via standard venipuncture to measure triglycerides.	Baseline, 3 months, 6 months
Change from baseline in visceral adiposity	The investigators will use a 5th generation General Electric Healthcare dual x-ray absorptiometry (DXA) scanner for regional fat measurements, the DXA software can be used to define standard regions that will allow comparability of measurements throughout the study.	Baseline, 3 months, 6 months
Change in baseline forced vital capacity	Spirometry will be used to measure lung function, specifically forced vital capacity (FVC).	Baseline, 3 months, 6 months
Change in baseline maximal voluntary ventilation	Spirometry will be used to measure lung function, specifically maximal voluntary ventilation (MVV).	Baseline, 3 months, 6 months
Change in baseline forced expiratory capacity in the first second	Spirometry will be used to measure lung function, specifically forced expiratory capacity in the first second (FEV1).	Baseline, 3 months, 6 months

Collaborators and Investigators

• Sponsor: Spaulding Rehabilitation Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 22, 2020
• Primary Completion (Anticipated): July 31, 2025
• Study Completion (Anticipated): July 31, 2026

Study Registration Dates

• First Submitted: June 25, 2020
• First Submitted That Met QC Criteria: July 1, 2020
• First Posted (Actual): July 7, 2020

Study Record Updates

• Last Update Posted (Actual): January 4, 2023
• Last Update Submitted That Met QC Criteria: January 3, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: Function Electrical Stimulation (FES)-Rowing
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Trauma, Nervous System; Spinal Cord Diseases; Wounds and Injuries; Spinal Cord Injuries; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Serotonin Receptor Agonists; Anti-Anxiety Agents; Buspirone
• Other Study ID Numbers: 2020P001363

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No